IN THE SPOTLIGHT

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

Nuvalent To Present Updated Data For ROS1-Selective Inhibitor, Zidesamtinib, And ALK-Selective Inhibitor, NVL-655, At The ESMO Congress 2024

Nuvalent To Present Updated Data For ROS1-Selective Inhibitor, Zidesamtinib, And ALK-Selective Inhibitor, NVL-655, At The ESMO Congress 2024

Practice Updates in Lung Cancer Stem From Biomarker Testing and Up-Front Immunotherapy

Practice Updates in Lung Cancer Stem From Biomarker Testing and Up-Front Immunotherapy

Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes

Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes

Lung Cancer Expert at ASCO: From Fatal to 'Chronic Disease'

Lung Cancer Expert at ASCO: From Fatal to 'Chronic Disease'

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lorbrena Yields “Unprecedented” Progression-Free Survival for ALK-Positive Lung Cancer

Lorbrena Yields “Unprecedented” Progression-Free Survival for ALK-Positive Lung Cancer

'Outstanding' 5 Year Progression-Free Survival With Lorlatinib in ALK+ NSCLC

'Outstanding' 5 Year Progression-Free Survival With Lorlatinib in ALK+ NSCLC

ASCO 2024: New study details longest progression-free survival ever reported in advanced NSCLC

ASCO 2024: New study details longest progression-free survival ever reported in advanced NSCLC

NVL-655 Receives FDA Breakthrough Therapy Designation in ALK+ NSCLC

NVL-655 Receives FDA Breakthrough Therapy Designation in ALK+ NSCLC

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC

FDA approves Alecensa for certain patients with ALK-positive lung cancer

FDA approves Alecensa for certain patients with ALK-positive lung cancer

FDA Approves Alectinib to Treat Patients With ALK-Positive NSCLC

FDA Approves Alectinib to Treat Patients With ALK-Positive NSCLC

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer

Treating Women With Lung Cancer: Screening, Treatment, and Sexual and Reproductive Health

Treating Women With Lung Cancer: Screening, Treatment, and Sexual and Reproductive Health

Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review

Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review

Dr Mark Socinski on How Targeted Therapies Have Impacted Lung Cancer Outcomes

Dr Mark Socinski on How Targeted Therapies Have Impacted Lung Cancer Outcomes

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations

ICYMI: Alecensa Exhibited Unprecedented Results for Patients with Early-Stage Lung Cancer

ICYMI: Alecensa Exhibited Unprecedented Results for Patients with Early-Stage Lung Cancer

Alectinib shows promise in early-stage ALK-positive non-small cell lung cancer

Alectinib shows promise in early-stage ALK-positive non-small cell lung cancer

Brigatinib Not Superior to Alectinib in ALK-Positive NSCLC

Brigatinib Not Superior to Alectinib in ALK-Positive NSCLC

Phase 3 Trial Results Show Adjuvant Alectinib Reduces Recurrence, Mortality in Early-Stage ALK-Positive NSCLC

Phase 3 Trial Results Show Adjuvant Alectinib Reduces Recurrence, Mortality in Early-Stage ALK-Positive NSCLC

Alectinib Meets DFS End Point in ALK+ Early-Stage NSCLC

Alectinib Meets DFS End Point in ALK+ Early-Stage NSCLC

Trial-first for Roche lung cancer ALK inhibitor

Trial-first for Roche lung cancer ALK inhibitor

Following in Tecentriq's footsteps, Alecensa gives Roche another win in early-stage lung cancer

Following in Tecentriq's footsteps, Alecensa gives Roche another win in early-stage lung cancer

Genentech's Alecensa shows promise in Phase III study for early-stage ALK-positive lung cancer

Genentech's Alecensa shows promise in Phase III study for early-stage ALK-positive lung cancer


Roche claims study success for targeted drug in early lung cancer


Roche claims study success for targeted drug in early lung cancer

A Look at NSCLC and Its Current and Emerging Therapies

A Look at NSCLC and Its Current and Emerging Therapies

dr Liu on the importance of NGS testing in NSCLC

dr Liu on the importance of NGS testing in NSCLC